UnitedHealth Group's Q1 2026 results reveal an adjusted EPS of $7.23 and a revenue of $111.7 billion, surpassing expectations of $109.65 billion. While the company faced a decline of approximately 1.1 million medical members, it raised its full-year 2026 adjusted EPS guidance to over $18.25. The firm's stock has risen 16.5% year-to-date, bolstered by analyst upgrades, including JPMorgan's target increase to $420. With $1.5 billion earmarked for AI investments, UnitedHealth is positioning itself for sustained growth amidst evolving market dynamics.
“UnitedHealth Group Inc. · was · the major gainer of the Dow”
“UnitedHealth · is a leading · home health and hospice provider · in the U.S.”
“Managed care providers like UnitedHealth Group and Humana · are leveraging · the Silver Tsunami · through specialized Medicare Advantage programs”
“UnitedHealth Group Incorporated (NYSE:UNH) · is one of the top · blue chip stocks · true”
“JPMorgan · lifted the price target on UnitedHealth Group Incorporated (NYSE:UNH) to · $420 · from $389”
“Goldman Sachs · has a Buy rating on the shares · UnitedHealth Group Incorporated (NYSE:UNH) · true”
“UnitedHealth Group Incorporated (NYSE:UNH) · was upgraded to · Buy from Hold · by Erste Group”
“UnitedHealth Group Incorporated (NYSE:UNH) · provides · healthcare coverage, data consultancy, and software services · true”
“UnitedHealth Group Incorporated · has pharmacy benefit management arm · Optum Rx · true”
“UnitedHealth's shares · have gained · 16.5% · in the year-to-date period”
“UnitedHealth · has outperformed · Zacks Medical - HMOs industry · +2.6% vs. -0.2%”
“UnitedHealth · expects total revenues to be · over $439 billion · 2026”
